|
|
Global R&D Product Pipeline
Clinical Research Studies-
Learn more about our current clinical trials.
-
Learn more about our products
Our product portfolio focuses on innovation in new products, improved products and manufacturing expertise thereby ensuring our continued growth.
Our balanced research and development portfolio is divided into three categories: life cycle management, market development and new product development. - Lifecycle management ensures continuous product improvement by maintaining and increasing competitiveness within our existing product range.
- Market development brings therapies to new markets and new indications by maximizing market opportunities for our existing product range.
- New product development creates specialty therapies to treat life-threatening diseases. It ensures long-term growth primarily through projects aligned with our current marketing channels.
For a brief description of any of the products listed in our pipeline please visit the Product Pipeline Description page.
| | Research / Pre-Clinical | Clinical Development | Registration/ Post-Launch | Life Cycle Management | | | | Immunoglobulins | | Haemophilia | | Specialty Products | | Influenza Vaccine |
| Market Development | Fibrinogen New Indications | PCC New Indications |
| | Hizentra® CIDP | Fibrinogen Aortic Surgery | | Zemaira® EU | | Berinert® SC |
| | Privigen® CIDP | | Biostate® EU | | Beriplex® US | Berinert® Self Admin |
| New Product Development | Novel Plasma Proteins | Rec Coagulation Factors | | rvWF-FP | | Partnered Vaccine Programs* | P. gingivalis/POD CRC-OHS/Sanofi* | | Discovery Projects | | CSL324 G-CSFR | | CSL346 VEGFB | | CSL334 IL-13R |
| | CSL654 rIX-FP | | CSL689 rVIIa-FP | | CSL627 rVIII-SC | | Partnered Vaccine programs* | CAM3001 GM-CSFR-AZ* | CSL112 reconstituted HDL | | CSL362 IL-3R |
| | Core Capabilities* Partnered Projects
For a brief description of any of the products listed in our pipeline please visit the Product Pipeline Description page.
|